PreTect See®The Best Protection Against Cervical Cancer Among Young Women

  • Not all HPV genotypes carry the same risk. The goal is to find the ones that trigger cervical cancer and pre-empt it.
  • Improved safety for young women.
  • Only for use by healthcare professionals.
  • More accurate individual patient management.
  • Reduced failure rate for cervical cancer detection in young women today.
  • Low cost and high detection capacity.
  • Intrinsic sample control to check specimen quality and detect factors inhibiting amplification.

E6/E7 mRNAand the Link to Cervical Cancer

  • Cervical Cancer is the most common cancer among women under 35 years of age.
  • Cervical Cancer case numbers are the same for 25-year-olds and 40-year-olds alike.
  • Cervical Cancer prevention in young women is a problem today.
  • PreTect SEE focuses on E6/E7 mRNA from HPV 16, 18, and 45 because 90% of Cervical Cancer cases in young women are caused by these genotypes. 1
  • Identifying E6/E7 mRNA expression from HPV 16, 18, and 45 enhances patient management at an individual level and avoids unnecessary treatment.

1 Munoz N, Int. J. Cancer: 111,278-285(2004).

NASBA TECHNOLOGY:Nucleic Acid Sequence-Based Amplification

PreTect SEE® is based on NASBA technology, an enzymatic amplification process that can amplify and detect RNA even in the presence of DNA. Unlike PCR, an amplification run is performed under isothermal conditions at 41°C, achieving a fast result.

Video Coming Soon


What about the HPV types not detected by PreTect SEE®?

PreTect SEE identifies cancer development caused by the three most important HPV types documented to be related to cervical cancer. These three HPV types are related to >90 % of all cervical cancer cases in women <35 years of age and > 80 % of all cervical cancer cases in women aged 35 to 49 years.1 Over 20 other HPV types have also been associated with cervical cancer. However, the number of women developing cervical cancer related to all these other HPV types is very limited, especially in women below 50 years of age.

1 Munoz (2004)

What is the added value of using PreTect SEE® compared to other DNA/RNA tests?

Other DNA/RNA tests have significantly lower specificity than cytology. PreTect SEE has significantly higher accuracy and specificity than cytology. This implies that the number of women in need of follow-up, and thereby the follow-up cost, will be reduced by 60-70 % compared to the use of other DNA/RNA tests.

What is the difference between a DNA test and PreTect SEE®?

A DNA test only detects the presence of HPV while PreTect SEE detects the oncogene activity (full length E6/E7 transcript) from HPV 16, 18, and 45.

Is PreTect SEE® clinically validated?

PreTect SEE is clinically validated according to the EU IVD regulations.

Molecular TechnologyOur Products

We develop medical devices and safe, state-of-the-art molecular technologies that empower you to take control of your health through prevention.

  • Mia Product Image with test tube

    Medical Devices

    User-friendly. Safe.

    The Mel-Mont Medical portfolio offers patented and versatile products for HR-HPV-related cancer prevention.

    View Products
  • photo of someone holding a medical device for in-vitro testing

    In Vitro Diagnosis

    Experience. Reliability.

    Our PreTect division offers molecular assays for nucleic acid amplification, along with an ISO 13485-certified HPV-mRNA molecular laboratory service.

    View Products
  • Two hands holding molecular consumables products

    Molecular Consumables

    Efficiency. Cost-effectiveness.

    Our consumables portfolio includes sample preparations for molecular testing and a transport medium.

    View Products

Have Questions? Our team is happy to answer any questions you may have.

Contact Us